Compare Sunrun Inc (RUN) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sunrun Inc vs BIO-TECHNE Corp — how do they compare? Sunrun Inc trades at $11.44 (market cap $2.73B), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: BIO-TECHNE Corp is far larger — about 4.1× Sunrun Inc's market cap, and BIO-TECHNE Corp pays a 0.45% dividend while Sunrun Inc pays none. Which is the better fit depends on your goals.
| RUN | TECH | |
|---|---|---|
Market Cap | $2.73B | $11.16B |
Sector | Technology | Health |
52-Week High | $21.41 | $72.12 |
52-Week Low | $9.07 | $43.31 |
Enterprise Value | $16.92B | $11.24B |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sunrun (RUN) trades at $11.44, down 3.46% today, with a bearish technical outlook. The stock shows strong profitability with a 17.88% net income margin and trades at a low P/E of 5.56. Recent news highlights a major partnership with Tesla and Renew Home for a 16-gigawatt virtual power plant, boosting growth prospects. Earnings have consistently beaten estimates, with Q1 2026 EPS of $0.62 versus -$0.05 expected.
The outlook is mixed: analyst consensus is bullish with a $16.27 price target, but cash flow concerns and high debt-to-asset ratio of 70.76% pose risks. The partnership with Tesla offers significant upside in the AI-driven energy demand sector, yet execution and financing challenges remain key hurdles for sustained growth.
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sunrun Inc
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
